Love Pharma Inc. (LUV.CN)
- GlobeNewswire
InvestmentPitch Media Video Discusses LOVE Pharma’s Plans to Continue Developing a Portfolio of Innovative Products such as Naltrexone Encompassing Transdermal Drug Delivery Applications for Addictions and Long-COVID
VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) continues with its plans to develop a portfolio of innovative products encompassing transdermal drug delivery applications. On October 11th, LOVE Pharma signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics, bringing significant IP related to the transdermal delivery of FDA approved Naltrexone, an opioid antagonist, primarily used to manage alcohol and or opioid use disorder
- GlobeNewswire
Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid
NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health and sexual wellness company, has been explicit about its plans to develop a portfolio of innovative products encompassing transdermal drug delivery applications in the addiction space, and a recent non-binding letter of intent to acquire Naltrexone Therapeutics Inc., would immediately bolster the company’s footprint in that space. At the same time, Naltrexone Therapeutics, a ph
